GOLDMAN SACHS GROUP INC - ALDEYRA THERAPEUTICS INC ownership

ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 138 filers reported holding ALDEYRA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ALDEYRA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,126,803
-32.0%
168,683
-14.6%
0.00%
Q2 2023$1,656,488
-41.9%
197,436
-31.3%
0.00%
-100.0%
Q1 2023$2,852,323
+1625.5%
287,243
+1109.4%
0.00%
Q4 2022$165,300
-83.6%
23,750
-87.4%
0.00%
Q3 2022$1,005,000
-78.7%
188,307
-84.1%
0.00%
-100.0%
Q2 2022$4,727,000
-23.5%
1,184,584
-14.8%
0.00%0.0%
Q1 2022$6,183,000
+1408.0%
1,391,018
+1254.9%
0.00%
Q4 2021$410,000
-61.8%
102,665
-15.9%
0.00%
Q3 2021$1,072,000
-90.6%
122,055
-87.9%
0.00%
-100.0%
Q2 2021$11,416,000
+1169.9%
1,007,619
+1232.0%
0.00%
Q1 2021$899,000
+204.7%
75,647
+76.2%
0.00%
Q4 2020$295,000
+34.7%
42,935
+45.2%
0.00%
Q3 2020$219,000
+41.3%
29,561
-20.3%
0.00%
Q2 2020$155,000
+124.6%
37,073
+32.6%
0.00%
Q1 2020$69,000
-88.0%
27,949
-71.8%
0.00%
Q4 2019$575,000
+35.9%
99,073
+23.4%
0.00%
Q3 2019$423,000
+336.1%
80,256
+394.3%
0.00%
Q2 2019$97,000
-13.4%
16,237
+31.2%
0.00%
Q1 2019$112,000
-27.3%
12,373
-33.3%
0.00%
Q4 2018$154,000
-59.3%
18,539
-32.4%
0.00%
Q3 2018$378,000
+223.1%
27,423
+76.2%
0.00%
Q1 2018$117,00015,5670.00%
Other shareholders
ALDEYRA THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Prosight Management, LP 908,488$6,232,0002.88%
Knoll Capital Management, LLC 569,405$3,906,0002.66%
Mesirow Financial Investment Management, Inc. 64,698$443,828,0001.40%
Ghost Tree Capital, LLC 650,000$4,459,0000.99%
Johnson & Johnson Innovation - JJDC, Inc. 594,834$4,081,0000.53%
Perceptive Advisors 6,285,458$43,118,0000.46%
Affinity Asset Advisors, LLC 100,000$686,0000.36%
ACUTA CAPITAL PARTNERS, LLC 192,500$1,321,0000.36%
Avidity Partners Management LP 1,435,000$9,844,0000.32%
APOGEM CAPITAL LLC 55,821$383,0000.26%
View complete list of ALDEYRA THERAPEUTICS INC shareholders